<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01782898</url>
  </required_header>
  <id_info>
    <org_study_id>STU00066623</org_study_id>
    <nct_id>NCT01782898</nct_id>
  </id_info>
  <brief_title>The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery</brief_title>
  <official_title>The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seventy percent of surgeries performed in the United States are done in an outpatient
      setting.Pain Control after ambulatory surgery is very challenging because patients do not
      have access to fast and potent intravenous medications Pain after ambulatory surgery is
      poorly controlled in the United States with up to seventy five percent of patients having
      moderate to severe pain after ambulatory procedures. Postoperative pain have been associated
      with serious morbidity, including myocardial infarction and pulmonary embolism.

      The use of intraoperative opioids can result in an exaggerated response to pain
      (hyperalgesia) and contribute to an exacerbation of pain after surgical procedures.Opioids
      are commonly given intraoperative, not in response to pain, but in response to hyperdynamic
      cardiovascular states. Esmolol is a short acting beta 1 antagonist that can be used to
      treat/prevent hyperdynamic states during surgery. More importantly, esmolol has been shown to
      have central antihyperalgesic effects that might contribute to a reduction in postoperative
      pain. It is therefore conceivable that the use of intraoperative esmolol instead of opioids
      to avoid hyperdynamic states during surgery can result in lower postoperative pain. Since
      postoperative pain can substantially affect postoperative quality of recovery, it is also
      conceivable that the use of intraoperative esmolol might result in an improved postoperative
      quality of recovery to surgical patients.

      The main objective of the current study is to examine the effect of intraoperative esmolol on
      postoperative quality of recovery. A secondary objective is to examine the effect of esmolol
      on postoperative pain.

      Significance: Postoperative pain after ambulatory surgery has been shown to be poorly managed
      in The United States. The goal of this study is to investigate if a change in the
      intraoperative pharmacologic management of patients undergoing ambulatory surgery can improve
      their postoperative quality of recovery and pain.

      The research question is; does the use of intraoperative esmolol improve postoperative
      quality of recovery after ambulatory surgery? Does the use of intraoperative esmolol improve
      postoperative pain after ambulatory surgery?

      The hypotheses of this study is; does the use of intraoperative esmolol improves
      postoperative quality of recovery after ambulatory surgery. The use of intraoperative esmolol
      reduces postoperative pain after ambulatory surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose a randomized double blinded placebo controlled clinical trial. Healthy females
      undergoing outpatient surgery will be recruited . Before surgery patients will be tested for
      pain sensitivity and threshold using a Pathway Pain &amp; sensory evaluation system (Medoc,
      Dunham, NC).Subjects will randomized using a computer generated table of random numbers to
      two groups: Active (Esmolol 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min titrated to
      keep heart rate between 50 and 70 BPM) or control (same volume of normal saline).The infusion
      will be discontinued at the end of the surgical procedure. Subjects will receive a standard
      anesthetic regimen: Induction (2 mg versed, 1-2mg /kg propofol and 0.6mg/kg of rocuronium),
      maintenance (Sevoflurane titrated to a Bispectral index between 40-60 and fentanyl 50 mcg q
      10 minutes to maintain blood pressure within 20% of baseline value. Patients will receive at
      the end of surgery ondansetron 4 mg IV to prevent nausea and/or vomiting. The postoperative
      analgesic regimen will also be standardized with hydromorphone 0.4 mg every 15 minutes to
      treat pain greater than 4/10 (scale where 0 means no pain and 10 means the worst possible
      pain) and hydrocodone 10 mg/acetaminophen 325 for pain control after discharge. Patients will
      receive ephedrine 5 mg q5minutes if blood pressure is lower than 40% baseline or if the heart
      rate is less than 40 beats per minute. Before hospital discharge patients will again be
      tested for pain sensitivity and threshold using a Pathway Pain &amp; sensory evaluation system
      (Medoc, Dunham, NC).

      The primary outcome will be a validated instrument to measure postoperative quality of
      recovery (QoR-40) that will be administered to patients by an investigator unaware of group
      allocation at 24 hours after the surgery.Other outcomes to be evaluated include;
      postoperative pain sensitivity and threshold, postoperative opioid consumption, postoperative
      pain, time to meet discharge criteria using a validated instrument (PADDS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qor-40 at 24 Hours Postoperative</measure>
    <time_frame>24 hours</time_frame>
    <description>Quality of recovery questionnaire score at 24 hours after surgery. Quality of recovery score 24 hours after the surgical procedure.Score of 40 is poor recovery and a score of 200 is good recovery.
Time frame for this evaluation is 24 hours after the surgical procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Opioid Consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>The total amount of opioid consumed by subject at 24 hours after surgery measured in IV morphine equivalents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Pain Reported by the Subject.</measure>
    <time_frame>24 hour</time_frame>
    <description>Post operative pain reported by the subject as determined as area under the numeric rating scale for pain versus time curve in the post anesthesia care unit ( score*min).Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve in the post anesthesia care unit ( score * min). A higher value indicates more pain over 24 hours.The range is 0 pain to x time in minutes x hour ( 60-1440 minutes) . The pain scores were collected at 15 minute intervals from the time of admission to the PACU to 24 hours after the surgical procedure. The area under the NRS pain scale versus time curve was calculated using the trapezoidal method as an indicator of pain burden during early recovery (Graph Pad Prism ver 5.03, Graph Pad Software INC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>.9 normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min</intervention_name>
    <description>Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min</description>
    <arm_group_label>Esmolol</arm_group_label>
    <other_name>Esmolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator: .9 normal saline</intervention_name>
    <description>Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,</description>
    <arm_group_label>.9 normal saline</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Female patients Undergoing outpatient hysteroscopic myomectomy surgery ASA PS I and II
        Age between 18 and 64 years Fluent in English

        Exclusion Criteria:

        History of allergy to beta-blocker History of chronic opioid use Pregnant patients BMI
        greater than 35 History of EKG abnormalities or cardiac arrhythmias Beta-blocker medication
        usage.

        Dropout criteria: Patient or surgeon request, Conversion of the surgery from laparoscopic
        to open.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gildasio De Oliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prentice Womens Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2013</study_first_submitted>
  <study_first_submitted_qc>January 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2013</study_first_posted>
  <results_first_submitted>February 4, 2016</results_first_submitted>
  <results_first_submitted_qc>March 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2016</results_first_posted>
  <last_update_submitted>October 5, 2016</last_update_submitted>
  <last_update_submitted_qc>October 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Gildasio De Oliveira</investigator_full_name>
    <investigator_title>Prinipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>MEDOC neuro sensory analyzer</keyword>
  <keyword>Pain</keyword>
  <keyword>Quality of recovery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Esmolol</title>
          <description>Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min: Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min</description>
        </group>
        <group group_id="P2">
          <title>.9 Normal Saline</title>
          <description>.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
Placebo Comparator: .9 normal saline: Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Esmolol</title>
          <description>Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min: Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min</description>
        </group>
        <group group_id="B2">
          <title>.9 Normal Saline</title>
          <description>.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
Placebo Comparator: .9 normal saline: Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="31" upper_limit="45"/>
                    <measurement group_id="B2" value="41" lower_limit="32" upper_limit="50"/>
                    <measurement group_id="B3" value="39" lower_limit="31" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <description>BMI is the abbreviation for body mass index which is represented by the following:
(kg/m^2)</description>
          <units>(kg/m^2)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" lower_limit="22" upper_limit="29"/>
                    <measurement group_id="B2" value="24" lower_limit="23" upper_limit="26"/>
                    <measurement group_id="B3" value="24" lower_limit="22" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraoperative Fentanyl (mcg)</title>
          <units>micrograms</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100" lower_limit="50" upper_limit="150"/>
                    <measurement group_id="B2" value="100" lower_limit="50" upper_limit="150"/>
                    <measurement group_id="B3" value="100" lower_limit="50" upper_limit="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical Duration</title>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82" lower_limit="67" upper_limit="99"/>
                    <measurement group_id="B2" value="72" lower_limit="66" upper_limit="83"/>
                    <measurement group_id="B3" value="77" lower_limit="67" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiologist Classification</title>
          <description>The grading system is to evaluate the degree of a patient's physical state before undergoing anesthetic procedure. 1-6 1 being healthy patient and 6 being brain dead.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ASA Class 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASA Class 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Qor-40 at 24 Hours Postoperative</title>
        <description>Quality of recovery questionnaire score at 24 hours after surgery. Quality of recovery score 24 hours after the surgical procedure.Score of 40 is poor recovery and a score of 200 is good recovery.
Time frame for this evaluation is 24 hours after the surgical procedure</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min: Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min</description>
          </group>
          <group group_id="O2">
            <title>.9 Normal Saline</title>
            <description>.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
Placebo Comparator: .9 normal saline: Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,</description>
          </group>
        </group_list>
        <measure>
          <title>Qor-40 at 24 Hours Postoperative</title>
          <description>Quality of recovery questionnaire score at 24 hours after surgery. Quality of recovery score 24 hours after the surgical procedure.Score of 40 is poor recovery and a score of 200 is good recovery.
Time frame for this evaluation is 24 hours after the surgical procedure</description>
          <units>units on a scale 40 low-200 high</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179" lower_limit="171" upper_limit="190"/>
                    <measurement group_id="O2" value="182" lower_limit="173" upper_limit="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.82</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Opioid Consumption</title>
        <description>The total amount of opioid consumed by subject at 24 hours after surgery measured in IV morphine equivalents.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min: Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min</description>
          </group>
          <group group_id="O2">
            <title>.9 Normal Saline</title>
            <description>.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
Placebo Comparator: .9 normal saline: Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Opioid Consumption</title>
          <description>The total amount of opioid consumed by subject at 24 hours after surgery measured in IV morphine equivalents.</description>
          <units>IV mg of morpine equivalents</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Pain Reported by the Subject.</title>
        <description>Post operative pain reported by the subject as determined as area under the numeric rating scale for pain versus time curve in the post anesthesia care unit ( score*min).Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve in the post anesthesia care unit ( score * min). A higher value indicates more pain over 24 hours.The range is 0 pain to x time in minutes x hour ( 60-1440 minutes) . The pain scores were collected at 15 minute intervals from the time of admission to the PACU to 24 hours after the surgical procedure. The area under the NRS pain scale versus time curve was calculated using the trapezoidal method as an indicator of pain burden during early recovery (Graph Pad Prism ver 5.03, Graph Pad Software INC.</description>
        <time_frame>24 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Esmolol</title>
            <description>Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min: Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min</description>
          </group>
          <group group_id="O2">
            <title>.9 Normal Saline</title>
            <description>.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
Placebo Comparator: .9 normal saline: Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Pain Reported by the Subject.</title>
          <description>Post operative pain reported by the subject as determined as area under the numeric rating scale for pain versus time curve in the post anesthesia care unit ( score*min).Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve in the post anesthesia care unit ( score * min). A higher value indicates more pain over 24 hours.The range is 0 pain to x time in minutes x hour ( 60-1440 minutes) . The pain scores were collected at 15 minute intervals from the time of admission to the PACU to 24 hours after the surgical procedure. The area under the NRS pain scale versus time curve was calculated using the trapezoidal method as an indicator of pain burden during early recovery (Graph Pad Prism ver 5.03, Graph Pad Software INC.</description>
          <units>(pain score * minutes ) in the PAC U</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" lower_limit="90" upper_limit="270"/>
                    <measurement group_id="O2" value="150" lower_limit="45" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.14</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Esmolol</title>
          <description>Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min: Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min</description>
        </group>
        <group group_id="E2">
          <title>.9 Normal Saline</title>
          <description>.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
Placebo Comparator: .9 normal saline: Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Nausea</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title vocab="Vomiting">Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gildasio De Oliveira, M.D.</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-4858</phone>
      <email>gjr@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

